



Annual DIA Preview Showcase Feature

PharmaVOICE is pleased to once again publish this Special Feature showcasing the new products, services, tools, and executive appointments and promotions from dozens of clinical-services companies that will be exhibiting at the DIA 45th Annual Conference in San Diego, June 21-25, 2009. For your convenience, we've divided the briefs into sections, including E-Solutions, What's New, and People. We also encourage you to log onto our digital edition at www.pharmavoices.com to view even more news and technologies from exhibiting companies.

We look forward to seeing you in San Diego. Please stop by the **PharmaVOICE** booth — No. 1300 — to learn about what's happening in the clinical-services arena.

STRENGTHENING SCIENCE AND SAFETY

Once again this year, the safety of medicines is top of mind at the Drug Information and Association's 45th Annual Conference.



Nancy Smith, Ph.D., former director of the Office of Training and Communications, CDER, at the U.S. Food and Drug Administration, is program chair for the Drug Information and Association's 45th Annual Conference.

We all share in the responsibility to work together to strengthen the science used in pharmaceutical product development, evaluation, and review," says Program Chair Nancy Smith, Ph.D., former director of the Office of Training and Communications, CDER, at the U.S. Food and Drug Administration. "We must find new tools to detect safety issues from preclinical testing through postmarketing and to improve communications about the safe use of medicines to patients, physicians, and other interested parties."

This year's meeting, which has the theme, "Better

Medicines: Improving Safety with Every Step," convenes more than 8,900 professionals, including representatives from more than 50 countries. Additionally, the meeting features more than 1,100 speakers, including representatives from FDA, EMEA, and other global regulatory agencies. More than 800 exhibiting companies will showcase their products and services in the interactive exhibit hall.

E-SOLUTIONS

The following briefs include information about new e-based clinically related solutions. The companies in this section are presented in alphabetical order.

Elsevier Partners with Communispace to Launch Global Online Community



Our goal for Innovation Explorers is to discover, in partnership with the researchers themselves, how Elsevier can help improve their research outcomes, says Jay Katzen of Elsevier.

Elsevier, in partnership with Communispace, has launched Innovation Explorers, an online community of 300 researchers from 69 countries to help identify, design, and deliver relevant products and services that resonate with and inspire research scientists around the world.

Communispace, which has created more than 325 online communities for the world's largest brands, is actively leading member activity and the delivery of insights.


"As a company, we're committed to finding innovative ways to better involve our users and buyers in our business, while providing them with a global platform to engage with one another," says Jay Katzen, managing director, academic and government products, at Elsevier.

In other moves, Elsevier has acquired the assets of Professional Development Software (PDS), the provider of SoftwareforNurses.com online learning education products. PDS has been integrated into Elsevier's Evolve Testing and Remediation product suite, bringing additional content to Elsevier's total cur-

riculum solution for nursing.

For more information, visit elsevier.com, or stop by Booth No. 529.

Web-Based i3Cube Simplifies Clinical-Trial Process



i3Cube was designed to provide our clients and clinical investigators with a simple, easy-to-use, and streamlined experience, says Glenn Bilawsky of i3.

i3's recently launched i3Cube is a Web-based clinical trial and data management technology that leverages i3's services and proprietary data to accelerate the clinical-trial process through automation and connectivity, allowing customers to make more rapid, informed decisions about their products.

i3Cube replaces the need for multiple systems and applications to manage study activities with an integrated solution that centralizes study information into a single location throughout the entire clinical trial process. The solution features intuitive dashboards that deliver real-time reporting and access to study information to sponsors and investigative site staff. Additionally, i3Cube provides greater speed and efficiencies through streamlined communication across the entire study team, study-specific automated workflow, and an integrated study library with version control, including an electronic trial master file.

"We brought together our use of proprietary healthcare claims data with our clinical research expertise and developed i3Cube to create time and cost efficiencies for our customers," says Glenn Bilawsky, CEO of i3.

For more information, visit i3global.com, or stop by Booth No. 107.



To access a Free Demo featuring i3Cube, go to i3global.com/solutions/i3Cube.

Medidata Rave Monitor Helps Manage Site Visits



The introduction of Rave Monitor enables us to provide research sponsors and CROs with even more ways to work effectively with their sites, says Medidata's Glen de Vries.

Rave Monitor is an extension of Medidata Solutions' Medidata Rave EDC and CDM solution that offers research sponsors and CROs a more efficient, compliant, and cost-effective way to manage site visits.

Site-monitoring activities represent one of the largest cost drivers in clinical research today, increasing the importance of improving the efficiency and effectiveness with which monitors or CRAs perform tasks.

The addition of Rave Monitor further extends the set of capabilities available to CRAs



by providing a new tool that makes a key part of their job — reporting on-site visits — more efficient.

“Medidata is committed to enhancing our customers’ competitive advantage by providing the tools and services that enable operational excellence across their entire clinical development team,” says President Glen de Vries.

Rave Monitor enhances cross-study operational visibility for study managers by providing users with online and offline visit report capture, approval workflow, and inter-study and cross-study status reporting, all within the context of their existing Rave deployment.

For more information, visit mdsol.com, or stop by Booth No. 701.

Nextrials Expands Prism’s Report Generation Functionality



It’s important for researchers to be able to generate reports customized for numerous audiences, ranging from safety analysts to clinicians, says Robert Barr.

Nextrials has increased the report generation functionality of its Prism data capture and clinical trial management platform to deliver more powerful data mining capabilities to customers.

With its improved ad hoc reporting feature, Prism users can now collect, summarize, and export data from tables within a single study or across multiple studies, creating efficiencies that save time and lower study costs. Its user-friendly graphical interface also includes advanced interactive data view formats, such as heat maps, in addition to bar graphs, pie charts, and other standard visual templates.


“Prism’s enhanced reporting capabilities make it easier to both compile trial data and drill down on data points of interest, providing better visibility of study results and reducing the opportunity for error,” notes Chief Technology Officer Robert Barr.

For more information, visit nextrials.com, or stop by Booth No. 1302.

Octagon Research Links Content Management Systems

Octagon Research Solutions’ ViewPoint Connector provides a way to link multiple data repositories either as a module to Octagon’s own ViewPoint process management solution or as stand-alone software that links to popular content management systems from companies such as Oracle and Microsoft.

ViewPoint Connector’s document and data integration features facilitate two-way communication with content management repositories, respect security defined within the content management system, and provide a fundamental building block for applications



ViewPoint Connector enables the integration of content from disparate repositories into standardized processes, says Octagon’s Aaron Miller.

that are integrating with content management systems. Octagon’s ViewPoint solution uses the optional Connector module to access content management systems while managing and controlling content-driven enterprise processes such as global regulatory submissions.

“The ViewPoint Connector module goes beyond existing technologies on the market by enabling a higher degree of integration and supporting routinely requested actions between applications,” says Aaron Miller, chief technology officer.

For more information, visit octagonresearch.com, or stop by Booth No. 513.

 To access a Free Demo featuring ViewPoint Connector, go to octagonresearch.com/viewpoint-connector.html

SAS Launches Physician Targeting Solution



As more pharma organizations restructure their approach to sales, the need for enhanced targeting tools increases, says Jason Burke of SAS.

SAS’ recently introduced physician targeting solution helps organizations apply predictive analytics to sales, CRM, and other customer data to go beyond deciling and target physicians based on profitability, retention, and future probability to prescribe.

Using a broad range of predictive modeling techniques, SAS for Physician Targeting enables organizations to understand the rules and characteristics

surrounding why physicians have prescribed in the past and apply those rules to predict who will be the prescribers of the future. Analytics can glean high-value targets from previously non-target populations.

“The SAS solution can mine prescription data with other data points, such as CRM data, managed care, health plan, and patient-level data to predict which physicians are responsible for the prescribing activity and segment accordingly,” says Jason Burke, global director of health and life sciences.

For more information, visit sas.com, or stop by Booth No. 301.

Thomson Reuters Adds to Ligent, IDRAC Product Lines

The healthcare and science business of Thomson Reuters has unveiled a number of additions and



The resulting reports are generated to the PDF specification as required by regulatory authorities, saving time and money, says Jeff Huntsman of Thomson Reuters.

upgrades to its family of Ligent solutions.

The recently introduced Ligent PublishPerfect is an enterprise publishing product that enables the efficient, integrated, and compliant publishing of reports from compilation to approval.

“In a market where time is of the essence, Ligent PublishPerfect allows users to remain in one program instead of going between several,” says Jeff Huntsman, VP, global sales, services and software solutions at Thomson Reuters.

Ligent PublishPerfect equips each unique document management system to create PDF documents that are fully compliant with the specifications of the regulatory authorities. Other features of the solution include a separate stand-alone publishing process outside of submission publishing; an entirely Web-based solution requiring no software installation; compliant outputs; and the capability to provide additional information publishing such as watermarks, overlays, and bookmarks.



To help our customers best apply Ligent InSight Publisher Select to their filing needs, we are offering Publisher Select customers product training at no additional cost, says Ligent’s Jim Nichols.

Thomson Reuters also has launched Ligent InSight Publisher Select, a new tool that enables small and emerging life-sciences companies to quickly create, review, amend, and submit regulatory dossiers.

“We are confident that Publisher Select will empower smaller and start-up life-sciences companies by streamlining their filing processes, thereby reducing their time to market,” says Jim Nichols, VP, Ligent software.

In other moves, Thomson Reuters has issued an upgrade to Ligent InSight Manager that offers more flexibility and usability for day-to-day processes, such as regulatory submissions.

Users can now plan and track submission activity in alignment with their own regulatory strategy with the Global Project Planning (GPP) wizard, which greatly reduces the data entry needed for the submission process.

Thomson Reuters also has launched IDRAC Notes, an add-on commenting feature that allows IDRAC to create, update, and share comments attached to IDRAC PDF documents.

For more information, visit thomsonreuters.com, or stop by Booth No. 821.



WHAT'S NEW

The following briefs include company news about new clinically related operations. The companies in this section are presented in alphabetical order.

Almac and PHT Team Up to Improve Clinical-Trial Productivity



Together, PHT and Almac are helping sponsors and sites remove time-consuming data cleaning tasks to focus on what they care about most: the health and safety of patients and conducting rigorous scientific research, says PHT's Philip Lee.

Almac Clinical Technologies and PHT have forged an alliance to improve clinical-trial productivity through a variety of education initiatives and data integration efforts that will reduce clinical-trial site burdens while improving study data collection and reporting.

PHT and Almac have agreed to provide consultation with clinical-trial sponsors on the difficult question of choosing the appropriate technology for studies involving electronic patient-reported outcomes (ePROs). The first joint data initiative involves integration of Almac's patient

screening and randomization data with PHT's handheld devices for ePRO studies.

"Our customers are constantly looking for ways to integrate multiple streams of e-clinical data and reduce the data entry burden on sites," says PHT CEO Philip Lee. "Our partnership with Almac offers added value for both sponsors and sites with one less data source to reconcile and the removal of a manual data entry step."

For more information about Almac Clinical Technologies, visit almacgroup.com, or stop by Booth No. 1301.

For more information about PHT, visit phtcorp.com, or stop by Booth No. 1124 and 1125.

BBK Establishes Osaka Location



Osaka is an optimal location from which to operationalize our patient recruitment efforts on behalf of our clients throughout the Asia-Pacific region, says BBK's Jeremy Buchman.

BBK Worldwide has opened BBK Worldwide — Osaka, which is committed to supporting Japanese pharmaceutical, biotech, and medical-device companies, as well as CROs and SMOs, to more rapidly and effectively enroll and retain patients as participants in clinical studies.

"Osaka seemed the ideal place to establish the operational base for our building of bridges — between recruitment barriers and enrollment solutions, and between cultures and

business practices," says Jeremy Buchman, who heads up the Osaka office.

For more information, visit bbkworldwide.com, or stop by Booth No. 1221.

Charles River Acquires Piedmont Research Center



As pharmaceutical and biotechnology companies increasingly choose strategic outsourcing as the means to accelerate their drug-development efforts, they need to rely on their service partners to provide scientific depth and expertise in therapeutic areas, says James Foster of Charles River.

Charles River Laboratories International has agreed to acquire the business and assets of Piedmont Research Center (PRC), a wholly owned subsidiary of PPD, for \$46 million in cash, significantly expanding the oncology expertise offered through Charles River's discovery and imaging services.

PRC provides preclinical discovery services focused on efficacy studies in oncology and other therapeutic areas for pharmaceutical and biotechnology clients, as well as non-GLP (good laboratory practice) pre-clinical efficacy testing services with expertise in the key therapeutic area of oncology. The

company also offers a range of other in vivo, in vitro, and analytical services to supplement its core pharmacology offering.

PRC continues to operate from its North Carolina headquarters as part of Charles River's Discovery and Imaging Services business.

"The addition of PRC's expertise, particularly in oncology, expands Charles River Discovery and Imaging Services' portfolio of efficacy testing services to better support our clients' needs," says James Foster, chairman, president, and CEO of Charles River.

For more information, visit criver.com, or stop by Booth No. 1731.

Chiltern Acquires Brazil-Based CRO Vigijn

Chiltern International has acquired Vigijn, a full-service CRO located in Sao Paulo, Brazil. Vigijn has experience conducting clinical trials in a variety of therapeutic areas, in particular, infectious disease, oncology, and respiratory.

The acquisition of Vigijn enhances Chiltern's growing presence in Latin America, which was established a year ago when the company began operations in Argentina under the leadership of Oscar Podesta, general manager for Latin America.

Two Vigijn staff have assumed new roles at Chiltern.

Dr. Eduardo Forleo has been appointed country manager for Brazil, and Elisa Halker serves as director of clinical operations for Brazil.

For more information, visit chiltern.com, or stop by Booth No. 203.

ERT Launches New Identity, Website



We see the change as a move forward in establishing the company as a reliable partner in products and services for clinical trials, says ERT's Michael McKelvey.

ERT, the new identity launched by the former eResearchTechnology, reflects the company's proactive organization that is committed to redefining and setting new standards of how clinical trials are successfully conducted.

ERT's brand strategy brings an enhanced visual identity to market as well as sharpened product positioning, a new Website, messaging, and corporate collateral. The ERT Website provides an enhanced online experience detailing information on ERT's portfolio of clinical-trial solutions as well as all company news and events, which serve to educate customers and facilitate inquiries.

As part of its new branding, ERT has introduced a new global platform of products and services that consists of four sub-brands: Cardiac Safety Solutions; EDC Solutions; ePRO Solutions; and ERT Clinical Research Consulting Group.

"Our new brand identity reflects ERT's dynamism and passion while continuing to instill the confidence and trust that the industry has in our products and services," says Michael McKelvey, president and CEO of ERT.

For more information, visit ert.com, or stop by Booth No. 507.

Icon, MedAvante Forge CNS Partnership



Icon is constantly striving to offer our pharmaceutical and biotechnology partners innovative clinical-trial solutions to enhance the drug-development process, says Icon's John Hubbard.

Icon and MedAvante have entered an alliance that aims to enhance precision and reduce high-failure rates in CNS trials.

"MedAvante has developed a platform that addresses a major cause of clinical-trial failure in CNS development: variability in both clinical diagnosis of the disorder being studied and ongoing assessment of the severity of the patient's symptoms in a consistent and standardized fashion," says John Hubbard, Ph.D., president, Icon

Clinical Research.

"This alliance extends our ability to offer our services across the industry and across the globe," adds Paul Gilbert, CEO of MedAvante. "Most importantly, however, is what this alliance provides to CNS drug



SUCCESS AHEAD IS ONLY POSSIBLE WITH
THE RIGHT PEOPLE BEHIND YOU.

Omnicare Clinical Research is a global CRO that keeps every facet of your research project working in perfect harmony. **Relevant experience. Problem-solving. Team-centric service.** Our level of synchronized project management delivers professionalism and precision at every point in the process, and a peace of mind that makes your life easier.

Learn more at www.omnicarecr.com/success

Visit us at DIA – Booth 639





developers, the ability on a larger scale to reduce the high rate of failed CNS clinical trials, which the industry recognizes as unacceptable in terms of cost and lost time.”

For more information about Icon, visit iconclinical.com, or stop by Booth No. 1307.

For more information about MedAvante, visit medavante.net, or stop by Booth No. 1822.

Lionbridge, Open Text Join Forces to Streamline Regulatory Compliance Solutions



Together, Lionbridge and Open Text provide our customers life-sciences regulatory expertise and reliable content management solutions, says Lionbridge's Satish Maripuri.

Lionbridge Technologies and Open Text have entered an alliance designed to ensure efficient, reliable integration of regulatory compliance and document management solutions for pharmaceutical companies and other organizations.

“By delivering a complete solution, we are helping our customers increase their process efficiency, improve productivity, and address compliance requirements while reaching new global markets,” says

Satish Maripuri, chief operating officer of Lionbridge.

For more information about Lionbridge, visit lionbridge.com, or stop by Booth No. 730.

For more information about Open Text, visit opentext.com, or stop by Booth No. 2024.

PharmaNet Establishes Clinical HR Business

PharmaNet Development Group has established PharmaNet Resource Solutions, a new clinical development human resourcing business that offers extensive industry experience in both clinical operations and contract staffing management. PharmaNet Resource Solutions provides several contract resourcing services, including on-demand staffing, strategic alliances, functional service staffing, and quality control services.

“We offer a strong management team and experienced clinical research professionals who provide clients practical, customized resource strategies to ensure their requirements are delivered on time and with the appropriate level of experience,” says Susan Seroskie, R.N., who heads the unit as VP, PharmaNet Resource Solutions. Ms. Seroskie joins PharmaNet from The Clinical Resource Network, where she served as senior VP, managed services.

In other expansion moves, PharmaNet has opened a new office in Sao Paulo, Brazil, to further enhance its Latin American presence. The company has been providing clinical-trial support in Latin America since 2002.

For more information, visit pharmanet.com, or stop by Booth No. 320 and 321.

Premier Research Expands Medical Device Operations to United States



Our clients have requested expanded medical-device services, and we are committed to responding to these needs, says Dr. Troy McCall of Premier Research.

Premier Research Group has expanded its medical-device operations to include full coverage in the United States. The company's medical device group has been offering clinical-trial services in Europe since 1997.

“Providing U.S. and EU services is a strategic focus for our company, and this strengthens our ability to respond to customers' needs,” says Premier Research Chief Operating Officer Troy McCall, Ph.D.

Premier's U.S. medical-device operations are overseen by Efraim Roe Kozorovitsky, executive director, medical devices.

For more information, visit premier-research.com, or stop by Booth No. 827.

Quintiles' Argentina Facility Earns CAP Accreditation



CAP accreditation validates the high-quality central lab services we offer at each of our sites around the world, says Quintiles' Marina Travacio.

Quintiles Transnational's central laboratory in Buenos Aires, Argentina, was recently accredited by the College of American Pathologists (CAP), giving Quintiles the largest CAP-accredited central laboratory network in the world and setting a standard for patient safety and faster drug development.

All nine Quintiles central labs are now CAP-accredited, including wholly owned facilities in China, India, Singapore, Scotland, South Africa, and the United States; and subcontractor labs in Argentina, Brazil, and Japan.

“We offer a combination of global resources, state-of-the-art buildings and equipment, staff experience and expertise, and high-quality and accurate service,” says Tom Wollman, senior VP, Quintiles Global Central Laboratories.

For more information, visit quintiles.com, or stop by Booth No. 329.

Radiant Research Partners with India-Based Spectrum Clinical Research

Radiant Research has established a strategic partnership with India-based Spectrum Clinical Research,

allowing Radiant to provide CRO and site services across both North America and India.

Both Radiant and Spectrum share expertise in a wide range of therapeutic areas, as well as a proactive recruitment approach to trials, using health screening campaigns to build databases in anticipation of enrollment.

For more information, visit radiantresearch.com, or stop by Booth No. 1904.

Smith Hanley Consulting Establishes Business Intelligence and Analytics Practice

Smith Hanley Consulting Group (SHCG), an iVentiv Health company, has launched a strategic business intelligence, data warehousing, and analytics practice as a complement to its staffing organization. The new practice assists SHCG clients in improving fact-based decision-making in their operations, financial management, and regulatory compliance areas.

As part of the launch, SHCG has appointed Bharat Chitnavis as director, business intelligence and analytics, with responsibility for leading the practice. Mr. Chitnavis reports to Managing Director Shelley Muhs, who has overall accountabilities of SHCG with the expanded business.

For more information, visit smithhanleyconsulting.com, or stop by Booth No. 722.

WCC Service Supports Early-Stage Clinical Studies

WorldCare Clinical (WCC) is now offering a new service, Collect, Ready, Hold, which supports sponsors conducting early-stage and Phase II clinical trials. The service helps to save time and money by allowing imaging data to be collected and standardized according to the imaging protocol, then held in a single, secure database until a central review of the data is requested.

Collect, Ready, Hold builds upon the company's extensive operational and regulatory expertise and employs WCC's WorldPro image management technology to acquire and prepare imaging data and store it all in a single, secure database. This gives sponsors complete control of the images acquired and helps them respond to the FDA or other regulatory agencies, streamlining review processes if needed.

“Sponsors conducting Phase II trials many times either don't have the funding in place or have yet to receive a request from the FDA to conduct a central review of their imaging data,” says Richard Walovitch, WCC's chief medical officer. “Collect, Ready, Hold was developed in response to these challenges as a cost-effective and preemptive approach for sponsors to collect, QC, and store images in a central database until it is determined if a central review of the imaging data is required.”

For more information, visit wccclinical.com, or stop by Booth No. 1501.



You need all sorts of people to form a great research team

We know that the range of skills, talent and experience required to deliver a successful clinical study can vary widely by project. Therapeutic area, study type, geography, scale and other factors all influence your needs.

We also know that more than ever you need the full range of people available to you in a flexible and responsive way, while at the same time taking good care of your budget.

This is why Chiltern Resourcing Solutions is structured to deliver you the ideal mix of dedicated clinical research professionals, be they CRAs, Project Managers, Data Managers, Statisticians, Physicians or others. And whether you are looking for a functional service provider, an individual or a team, we will get outstanding people to you when, for how long and where in the world you want them.

To give your study the best possible chance of success – or to be part of a great team – simply contact us.

Chiltern is an equal opportunity employer and we ensure that we give full consideration to individual needs for work life balance, personal fulfillment and growth. We are constantly looking for talented individuals at all levels of experience. If you want more information or would like to register your details with us please visit the Careers section of our website.



UNDERSTANDING RESOURCING

Americas +1 (423) 968 9533 Europe/Asia +44 (0) 1753 512 000 info@chiltern.com www.chiltern.com

Early Phase · Global Clinical Development · Late Phase · Biometrics · Medical and Regulatory Affairs · Resourcing Solutions



WHO'S WHO

The following briefs include personnel news, new appointments, and promotions in the clinical arena.

Dr. Theresa Bromley Dr. Howard Goldberg Dr. Marian Ormont

ePharmaSolutions Expands CNS Department

ePharmaSolutions (ePS), a provider of clinical services and trial management technologies, has announced the addition of three key industry veterans, in part to support the expansion of its global CNS rater services department.



ePS has named Theresa Bromley, Ph.D., associate director of rater training, with responsibility for supporting the development and deployment of several Web-based technologies that support the training, certification, and ongoing monitoring of raters in every continent for more than 100 psychometric scales.

Dr. Bromley was most recently with United BioSource.

Dr. Bromley is a licensed psychologist with more than 15 years of private practice and pharmaceutical industry experience.

Howard Goldberg, Pharm.D., has joined ePS as senior VP of business development, after 10 years as the president of ClinPhone, which was acquired by Parexel International in August 2008.



Marian Ormont, M.D., has been appointed medical director. Like Dr. Bromley, she is responsible for supporting ePS' global rater-monitoring technology, and joined ePS from United BioSource.

Dr. Ormont is a board-certified psychiatrist with more than six years of industry experience managing rater services for CNS studies on a global scale.

Before joining the industry, Dr. Ormont was a principle investigator and had a private practice.

For more information, visit epharmasolutions.com, or stop by Booth No. 1712.

Dr. E. James (Jim) Emerson

etrial's Hires Consultant as Tech Development VP



etrial's Worldwide, a provider of adaptive e-clinical software and services designed to optimize clinical trial management, has named E. James (Jim) Emerson, Ph.D., VP of technology and development. In this role, Dr. Emerson is focusing on the development of new, innovative, and viable products designed to drive quick and sustained revenue streams.

Dr. Emerson previously served as a consultant to etrial's. He has an MBA from Seton Hall University and a Ph.D. in computer science from the New York Polytechnic Institute.

For more information, visit etrial's.com, or stop by Booth No. 1321.

Bill Gwinn

i3 Names Clinical Informatics VP



i3 has appointed Bill Gwinn VP of the clinical informatics team housed within its Pharma Informatics business. Mr. Gwinn joins i3 as an expert in quantitative analysis for selecting the best clinical trial sites and finding new patients. His past experience includes positions at Inclinx and The Medstat Group at Thomson Reuters. i3, a global Ingenix company, provides integrated scientific strategies and solutions.

For more information, visit i3global.com, or stop by Booth No. 107.

James Kirk Richard (Rich) Pilnik

Quintiles Strengthens Businesses Units

In the wake of Quintiles Transnational's 2008

acquisition of Eidetics, James Kirk has been named practice leader for Eidetics, which has become the market intelligence and decision analytics practice of Quintiles Consulting.

Mr. Kirk was one of Eidetics' original partners and has been with the firm since 1988. He holds a master's degree from Stanford University.

In this new role, Mr. Kirk leads the team of Eidetics professionals on projects that address complex business challenges in nearly every disease category, from preclinical go/no-go decisions to post-launch market defense.



In other moves, Quintiles Transnational has named Richard (Rich) Pilnik to serve as president of Innovex, a Quintiles company that helps pharmaceutical and biotech companies maximize commercial success across a product's life cycle.

Mr. Pilnik has 25 years of experience in the pharmaceutical commercial sector, most recently as group VP and chief marketing officer for Eli Lilly.

He received an MBA from the Kellogg School of Management at Northwestern University.

Quintiles provides development, financial, and commercialization solutions to the pharmaceutical and biotechnology industries.

For more information, visit quintiles.com, or stop by Booth No. 329.

FEATURED DIA EXHIBITING COMPANIES AT A GLANCE

Almac Clinical Technologies specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical-trial process. For more information, visit almacgroup.com or Booth No. 1301.

BBK Worldwide is a patient recruitment and e-business solution company for clinical R&D and product marketing segments. For more information, visit bbkworldwide.com or Booth No. 1221.

Charles River Laboratories International Inc. provides products and services to accelerate research and drug-development efforts. For more information, visit criver.com or Booth No. 1731.

Chiltern International Ltd. is a global contract research organization with experience in conducting and staffing global Phase I to Phase IV clinical trials across a broad therapeutic range. For more information, visit chiltern.com or Booth No. 203.

Elsevier is a publisher of scientific, technical, and medical information products and ser-

vices. For more information, visit elsevier.com or Booth No. 529.

ePharmaSolutions (ePS) is a provider of technology-based clinical services that help improve the way sites are selected, trained, activated, and supported. For more information, visit epharmasolutions.com or Booth No. 1712.

ERT provides centralized ECG and e-clinical technology, ePRO, and other services designed to support clinical trials. For more information, visit ert.com or Booth No. 507.

Etial's Worldwide Inc. is a provider of adaptive e-clinical software and services to optimize clinical-trial management. For more information, visit etrial's.com or Booth No. 1321.

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product life cycle. For more information, visit i3global.com or Booth No. 107.

Icon Plc. is a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical-device industries.



PharmaVOICE Webcast Network – Podcasts, Videocasts, and Webseminars

The following is a list of archived Podcasts and WebLinx Interactive Webseminars and Videocasts related to the clinical research and services arenas that PharmaVOICE and industry thought leaders have conducted throughout the year. To access any of PharmaVOICE's archived episodes, please visit pharmavoice.com.



Redefining the CRO

Thought Leader: Bob Burford Ph.D.,
Managing Director, Aptuit Consulting

For more information, visit aptuit.com,
or stop by Booth No. 1606.



The Next Generation of Clinical Operations

Thought Leaders: Nagaraja Srivatsan, Head of Life Sciences, North America, and Kaushik Bhaumik, Global Practice Leader, Consulting and BPO, Cognizant

For more information, visit cognizant.com,
or stop by Booth No. 211.



Better Standards and Metrics for CROs and Sponsors

Thought Leaders: Gregg Dearhammer, i3 Statprobe, and Karen Goss, i3 Drug Safety

For more information, visit i3global.com,
or stop by Booth No. 107.



Late-Phase Research Success: Leveraging Secondary Data

Thought Leader: Cyndi Verst, Pharm.D., M.S., Senior VP, Global Late Phase, i3 Innovus

For more information, visit i3global.com,
or stop by Booth No. 107.



Named Patient Programs: A Three-Part Series

Thought Leaders: Natalie Douglas, CEO, Maria Kempshall, Head of Regulatory Affairs and Quality Assurance, and John Lagus, VP of Business and Corporate Development

For more information, visit idispharma.com,
or stop by Booth No. 235



E-Clinical Moves Into the Mainstream

Thought Leader: Stacey Arrambide, VP, Statistics and Data Management, inVentiv Clinical Solutions

For more information, visit inventivclinical.com,
or stop by Booth No. 621.



Procuring and Managing Clinical Staffing Resources

Thought Leader: Stephen Cottrell, Executive VP, Operations and Business Development, inVentiv Clinical Solutions

For more information, visit inventivclinical.com,
or stop by Booth No. 621.



Planning for Electronic Patient Recorded Outcomes: A Guide to Global Clinical Trials Success

Sponsored by: Lionbridge
Thought Leaders: Hannah O'Gorman, ClinPhone, and Mark Wade, Lionbridge

For more information about Lionbridge,
visit lionbridge.com, or stop by Booth No. 730.



Making Pharmacovigilance Work

Thought Leaders: Uwe Maennl, M.D., Ph.D., and Gadi Saaroni, Parexel Consulting

For more information, visit parexel.com,
or stop by Booth No. 1701



Making Headway in Shifting Winds by Maximizing Value: A Three-Part Series

Thought Leaders: Michael Hagan and James C. Kirk, Quintiles Consulting; James Featherstone, Bruce E. Johnson, and Heidi Hunter, Quintiles; and John Doyle, Dr.P.H., and Geoff Garabedian, Quintiles Consulting

For more information, visit quintiles.com,
or stop by Booth No. 329.

For more information, visit iconclinical.com or Booth No. 1307.

Lionbridge Technologies Inc. is a provider of translation, development, and testing services for the pharmaceutical and biotechnology industries. For more information, visit lionbridge.com or Booth No. 730.

MedAvante Inc. is a global provider of centralized expert psychological rating services. For more information, visit medavante.net or Booth No. 1822.

Medidata Solutions Worldwide provides hosted e-based and clinical-development solutions for pharmaceutical and biotechnology companies. For more information, visit mdsol.com or Booth No. 701.

Nextrials Inc. provides Web-based software solutions and tools for clinical research. For more information, visit nextrials.com or Booth No. 1302.

Octagon Research Solutions Inc. provides regulatory, clinical, and process software and services to the life-sciences industry. For more

information, visit octagonresearch.com or Booth No. 513.

Open Text Corp. provides enterprise content management solutions. For more information, visit opentext.com or Booth No. 2024.

PharmaNet Development Group Inc. provides clinical development services to the life-sciences industry. For more information, visit pharmanet.com or Booth No. 320.

PHT Corp. provides electronic patient reported outcome (ePRO) solutions used in biopharmaceutical clinical trials. For more information, visit phtcorp.com or Booth No. 1124.

Premier Research Group Ltd. provides specialized outsourced services for the global health-care community. For more information, visit premier-research.com or Booth No. 827.

Quintiles Transnational Corp. provides development, financial, and commercialization solutions to the pharmaceutical and biotechnology industries. For more information, visit quintiles.com or Booth No. 329.

Radiant Research Inc. is a clinical research

company offering study conduct, development, and centralized patient recruitment services. For more information, visit radiantresearch.com or Booth No. 1904.

SAS provides business analytics software and services. For more information, visit sas.com or Booth No. 301.

Smith Hanley Consulting Group LLC, an inVentiv Health company, is a specialized recruiting services organization. For more information, visit smithhanleyconsulting.com or Booth No. 722.

Thomson Reuters provides information and knowledge to accelerate research, discovery, and innovation for life-sciences companies. For more information, visit thomson-reuters.com or Booth No. 821.

WorldCareClinical (WCC) is an imaging contract research organization that supports clinical trials. For more information, visit wccclinical.com or Booth No. 1501.

SEE DIGITAL EDITION FOR BONUS CONTENT
WWW.PHARMAVOICE.COM



THE KEYNOTE AND FEATURE PRESENTATIONS

The keynote speaker is Dr. Nancy Snyderman, chief medical editor at NBC News. Dr. Snyderman has reported on wide-ranging medical topics affecting both men and women and has traveled the world extensively, reporting from many of the world's most troubled areas. She is Associate Professor of Otolaryngology, Head and Neck Surgery, at the University of Pennsylvania.

One highlight is a multitrack plenary session titled Improving Safety with Every Step: Pillars of the Pharmaceutical Landscape. This session will feature industry, regulatory agencies, academia, and patient groups as they share their perspectives on how to enhance patient safety. With increased awareness on drug safety due to drug withdrawals and the FDAAA of 2007, this session will discuss the importance of collaboration among the various groups, what is currently being done, and what needs to happen in the future to ensure that patients get the necessary information to make informed health decisions.

One featured session is Pharma in the New Age of Transparency, where experts in health-care policy will discuss how public scrutiny of the industry will impact the industry and public policy as the nation debates major changes in healthcare delivery.

Another featured session looks at the many challenges confronting the life-sciences industry today. High-quality management of research and development is critical to the future of the

entire industry. Based on the results of a survey recently completed to investigate best project management practices in R&D drug development, a perspective will be provided on how project management can meet these challenges and provide huge competitive advantage to companies willing to embrace the cultural and process changes required.

Making the Most of the Meeting

The Annual Meeting features more than 350 sessions and 34 preconference tutorials focusing on issues affecting global drug discovery and development, including hot topic sessions. Hot topics include:

- Accelerated Development Time
- Adaptive Trial Design
- Biomarkers
- Clinical Safety and Pharmacovigilance
- Critical Path Initiative
- Lean Six Sigma
- Pharmacogenomics and Personalized Medicines
- Pharmacovigilance and Risk Management

New this year is the creation of three megatracks designed to enhance the quality of the presentations, minimize overlap of similar session topics in different tracks, and promote broader discussion and a fuller understanding of the topics presented. Megatracks include: Information Technology, Clinical Research, and Advertising/Marketing/Medical Communications.

Global drug development is also a key focus of the meeting. This year's event will include sessions on issues affecting key regions of the world, including: Asia Pacific, Australia, Emerging Markets, Europe, India, and Latin America

The Asia-Pacific region, in particular, will be a key focus. The meeting will provide the opportunity to speak face to face with representatives from more than 30 international regulators in attendance, such as:

- Australia Therapeutic Goods Administration
- China State Food and Drug Administration (SFDA)
- India Directorate of Drugs Control
- Japan Pharmaceuticals and Medical Devices Agency (PMDA)
- Taiwan Center for Drug Evaluation
- Korean Food and Drug Administration
- Korean Ministry for Health, Welfare and Family Affairs
- Taiwan Department of Health
- Vietnam Ministry of Health

Another new feature this year is that all paid registrants of the Annual Meeting receive free online access to all available sessions, captured in digital audio with synchronized PowerPoint presentations through the DIA Live Learning Center. This access allows attendees to review the sessions they attended or those they missed. Attendees will be able to access the valuable professional development content from the Annual Meeting for a period of six months after the event.

E-SOLUTIONS

Additional DIA exhibiting companies that have new technologies related to the clinical arena. The companies in this section are presented in alphabetical order.

Acorn CRO Introduces Site Tracking and Recruitment Tool

Acorn CRO has launched STAR (Site Tracking and Recruitment), a tool aimed at accelerating the site selection and patient recruitment process for clinical studies, increasing the accuracy and transparency of the site feasibility/selection process, and saving valuable time during the clinical study start-up phase.

STAR uses a dedicated technology tool to speed the process of selecting study sites, as well as site repositories based on sponsor requirements. The solution also automates the study feasibility process, seamlessly sends reminder notifications, and generates site feasibility metrics in real time.

For more information, visit acorncro.com, or stop by Booth No. 2039.

ISI Solution Streamlines Regulatory Submissions on Microsoft Software Platform

Image Solutions (ISI) has expanded its relationship with Microsoft to offer a SharePoint-compatible version of its ISI Regulatory Solutions Suite (RSS).

Through the integrated solution, ISI's RSS — which includes ISI's flagship products eCTDExpress and ISIPublisher — is now built upon and seamlessly integrates with Microsoft Office SharePoint Server 2007, offering several new features that remove administrative burdens from regulatory departments to accelerate timelines for bringing drug therapies to market.

"SharePoint Server allows us to create a familiar collaboration environment that enables life-sciences companies to easily deploy our proven solutions," says

Jinsoo Kim, CEO and president of ISI.

For more information, visit imagesolutions.com, or stop by Booth No. 851.

MDS Pharma Services Launches OncoPredictor for Cancer Drug Development

Through a strategic collaboration with Compendia Bioscience, MDS Pharma Services has delivered OncoPredictor, a solution designed to improve the development of drugs to treat cancer.

OncoPredictor combines MDS Pharma Services' OncoPanel with Compendia Bioscience's Oncomine for a solution that helps identify cancer patient populations most likely to respond to a new or existing cancer therapy. As a result, research is more efficient and



therapies can be targeted to those most likely to benefit.

“Our pharmaceutical and biotechnology clients seek to determine the efficacy of their compounds across cancer genotypes and patient phenotypes,” says MDS Pharma Services President David Spaight. “OncoPredictor helps provide the answer with technology for information-based lead selection, predictive in vivo study design, and biomarker development.”

For more information, visit mdsps.com, or stop by Booth No. 721.

Microsoft Targets Discovery of Personalized Medicines

Microsoft’s recently launched software system, Amalga Life Sciences, is designed to transform health-care and life-sciences research data into the critical knowledge needed for the discovery of new personalized treatments.

Amalga Life Sciences helps organizations achieve the next level of research capability by connecting data and investigators in new ways through novel storage capabilities, ontology management functions, and

a semantic query environment powered by a next-generation reasoning engine.

For more information, visit microsoft.com, or stop by Booth No. 931.

Updated Relsys System Includes Productivity Enhancements

The latest version of Relsys International’s Argus Safety Suite drug safety and risk management system features productivity, performance, and usability enhancements that help pharmaceutical clients rapidly process and manage all of their reporting obligation.

Argus Perceptive 5.0 enables powerful risk assessments with greater data accuracy, ensuring that medical reviewers get advanced notice of signals, potentially leading to earlier risk identification.

For more information, visit relsys.net, or stop by Booth No. 1621.

Wolters Kluwer Partners with QlikTech, Netezza on Solution

Wolters Kluwer Health has deployed a new prod-

uct application that combines its database resource with QlikView’s software for information providers and Netezza’s data warehouse appliance, offering brand managers and other executives quick, cost-effective access to key market data and customized dashboards.

Wolters Kluwer Health’s Source market database captures drug prescription data from pharmacies, hospitals, and healthcare providers. These data deliver insights into the drivers of a brand’s market performance.

The new application provides an on-demand Web portal to access the Source database directly, providing clear visibility into the real-time performance of sales and marketing programs.

“We can quickly design customized dashboards for clients, enabling us to more efficiently meet client needs,” says Peter Demogenes Sr., director, product management, for Wolters Kluwer Health. “QlikView’s ability to merge data from multiple sources allows us to provide updates to the database faster than before.”

For more information, visit wkhealth.com, or stop by Booth No. 1842.

WHAT’S NEW

The following briefs include company news about new clinically related operations. The companies in this section are presented in alphabetical order.

AAIPharma Forms Alliance With Drug-Delivery Firm Emisphere

AAIPharma has partnered with Emisphere Technologies to extend the application of Emisphere’s Eligen delivery technology to AAIPharma’s drug development services.

Emisphere’s proprietary Eligen technology is a delivery method for therapeutic molecules and nutritional supplements that improves the ability of the body to absorb small and large molecules by means other than injection. AAIPharma currently provides drug product formulation development services to Emisphere.

“This strategic alliance with Emisphere is within our strategy to offer drug delivery options to our pharmaceutical and biotech customers,” says L. Lee Karas, senior VP of AAIPharma’s pharmaceutical services business. “The combination of the Emisphere Eligen technology and AAIPharma’s drug development services is of tremendous value to customers seeking proprietary and unique oral drug delivery options.”

For more information, visit aaipharma.com, or stop by Booth No. 445.

ACM Global Central Partners With Chindex to Provide Central Lab Services in China

ACM Global Central Laboratory is partnering with Chindex International to provide central lab services in

China at Chindex’s United Family Hospitals in Beijing. ACM Global Central Lab’s global operations extend to more than 60 countries, including the Americas, Europe, Australia, Asia, Israel, South Africa, and India, with all tests conducted and managed from central lab facilities with seamless data management providing a single database.

For more information, visit acmgloballab.com, or stop by Booth No. 726.

Covance Expands Operations in Europe, South America

Covance has made a number of expansions to its facilities in Europe and South America, including the acquisition of a clinical research company in Switzerland.

The acquisition of Swiss Pharma Contract, a 50-bed clinical research company based in Basel, significantly increases Covance’s early clinical development footprint in Europe and gives clients access to special patient populations for Phase I/IIa clinical studies.

Covance also has made a significant expansion of its biotechnology services facility in Harrogate, United Kingdom, and has become one of a few CROs to receive a cGMP manufacturing license from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA). The expanded Harrogate services facility includes upgraded infrastructure and equipment for

biopotency, molecular biology, and protein chemistry services. As a cGMP-licensed manufacturer in the United Kingdom, Covance now offers fully cGMP-compliant biotechnology studies to help customers fulfill global regulatory requirements for biotechnology studies.

In South America, Covance has opened clinical development offices in Santiago, Chile, and Lima, Peru, and expanded its existing office in Buenos Aires, Argentina. These openings further extend the company’s global clinical development presence to increase patient access and reduce clinical development timelines. The new clinical offices located in Santiago and Lima support staff in Chile and Peru, including Covance’s regional network of field-based clinical research associates throughout Latin America.

For more information, visit covance.com, or stop by Booth No. 1515.

J&J Pharma R&D Opens Facilities in Shanghai and Mumbai

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), a unit of Johnson & Johnson, has expanded its global research network with new facilities in China and India.

J&JPRD has established a new research and development center in Shanghai that also serves as J&JPRD’s Asia R&D headquarters, with Dr. Lily Lee heading the business’ Asia/Pacific R&D efforts.



The Shanghai site embraces the company's philosophy of open innovation and collaboration by developing a broad regional network and combining internal research, expertise, and capabilities with external knowledge/innovation, expertise, or approaches to accelerate innovation in product and technology development.

J&JPRD has also opened a late-phase new chemical entity (NCE) analytical and pharmaceutical development center (APDC) based in Mumbai. The APDC, the first of its kind in India, plays a key role in addressing major global healthcare challenges, many of which also address key issues facing India and the region. NCEs to be developed by the facility include a potential new treatment for tuberculosis, a late-stage HIV compound, and a number of products designed to treat multidrug-resistant bacteria.

For more information, visit jnpharmarnd.com, or stop by Booth No. 216.

Medifacts Partners with Suzuken for Cardiac Safety Services in Japan

Medifacts International has formed a strategic alliance with Suzuken, one of Japan's largest cardiac safety services providers, to deliver advanced technology and centralized services to the biopharmaceutical and medical-device industry in Japan.

"Our strategic alliance sets a new standard in the service delivery of Japanese as well as global studies; we are now able to provide our global clients with full-service cardiac safety support operating from hubs in Japan, China, Europe, and the Americas," says Michael Woehler, president and CEO of Medifacts.

For more information, visit medifacts.com, or stop by Booth No. 2125.

Perceptive Informatics Adds Japanese Kanji to Web Response System

Perceptive Informatics has expanded the number of languages supported by its ClinPhone Interactive Web Response System (IWRS), by including Japanese kanji, the Chinese characters used in the Japanese writing system. With this latest enhancement, IWRS now supports more than 80 languages via the Web, including Chinese, Greek, Hebrew, Hungarian, Korean, Polish, Romanian, Russian, Slovak, Thai, Turkish, and Ukrainian.

The Perceptive Informatics' data center provides 24/7 global support for clinical trials involving multiple countries, time zones, and languages.

For more information, visit perceptive.com, or stop by Booth No. 1707.

Phase Forward Purchases Clinical Data Solutions Provider Waban Software

Phase Forward has acquired privately held Waban Software, a provider of platform solutions for the automation and compliance of clinical data analysis and reporting, for \$14 million in cash.

Waban, based in Cambridge, Mass., and with operations in Mumbai, India, has become the Waban Software Group within PhaseForward, extending its portfolio of clinical data solutions and enabling an integrated end-to-end solution from study setup through analysis and submission.

For more information, visit phaseforward.com, or stop by Booth No. 729.

PPD Acquires Magen BioSciences and AbCRO

PPD has purchased Magen BioSciences, a biotechnology company focused on dermatologic therapies, for \$14.5 million in cash, expanding its compound partnering program into dermatology, initially in the indications of psoriasis, atopic dermatitis, and acne.

With the acquisition, PPD gains compounds through Magen's exclusive license to develop and commercialize preclinical compounds discovered by Eli Lilly for dermatologic therapeutics.

PPD CEO Fred Eshelman notes that the market is growing for dermatologic products, which generally present fewer development hurdles than other therapeutics and have a more straightforward path to regulatory approval.

Sandra Luikenhuis, Ph.D., who was integral in founding and growing Magen, has joined PPD with the acquisition and is overseeing development of these compounds in her role as executive director, dermatology.

PPD also has acquired AbCRO, expanding its CRO operations in central and eastern Europe and strengthening its ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification, and regulatory affairs services to its growing client base in the Balkans and surrounding countries. More than 230 employees have joined PPD with the AbCRO acquisition, including Co-founders Dana Leff, CEO, and Chairman Christa Pleasants.

In other moves, PPD has opened an office in Tokyo, expanding its Phase II to Phase IV development services in response to growing client demand in eastern Asia.

For more information, visit ppdi.com, or stop by Booth No. 546.

WHO'S WHO

The following briefs include personnel news, new appointments, and promotions in the clinical arena.

Ardy Arianpour

Ambry Genetics Chooses Business Development Director

Ambry Genetics, a commercial clinical laboratory providing genetic services focused on clinical diagnostics, pharmacogenomics, and research support, has hired Ardy Arianpour as director of business development for genomic services. He was most recently manager of business development for Cogenics.

For more information, visit ambrygen.com, or stop by Booth No. 2047.

Bill Baxter

CIS Adds Government Programs Consultant

Pharmaceutical compliance consulting firm Compliance Implementation Services (CIS) has added Bill Baxter as a consultant to its management team. In this role, Mr. Baxter is responsible for helping to guide CIS' continued growth, specifically in the government programs area.

Mr. Baxter has almost four decades of diverse pharmaceutical industry experience in areas such as Medicaid contracting, government affairs, sales, sales management, and training. Before joining CIS, he served as chairman of State Health Care Policy Council, an organization tasked with providing a forum for Johnson & Johnson's operating company management to review emerging healthcare issues and developing policy. He was also a participating member of J&J's Medicaid and Medicare task forces.

For more information, visit cis-partners.com, or stop by Booth No. 2242.

William Broucek

Velos Adds Senior Director

Velos, a provider of clinical-trial management information systems, has appointed William Broucek as senior director, professional services. Mr. Broucek is responsible for ensuring that superior customer service is sustained amid the continued expansion of

Velos' business. Before joining Velos, Mr. Broucek held senior positions in professional services and implementation management with Bay Area companies.

For more information, visit velos.com, or stop by Booth No. 1840.

John Chiminski David Guelzow John Kay Kevin Tilley

Catalent Makes Executive Appointments

Catalent Pharma Solutions, a provider of advanced technologies, and development, manufacturing, and packaging services for pharmaceutical, biotechnology, and consumer healthcare companies, has named a new CEO and announced a number of additions to the printed components business of its packaging services segment.

Catalent has appointed John Chiminski to succeed



George Fotiades as president and CEO. Mr. Fotiades, who had been serving as president and CEO on an interim basis, continues as Catalent's chairman.

Mr. Chiminski joins Catalent after more than two decades at GE, most recently serving as president and CEO of the GE Medical Diagnostics division of GE Healthcare. He received an M.S. in electrical engineering from Purdue University and a Master of Management degree from the Kellogg School of Management at Northwestern University.

In the printed components business of Catalent's packaging services segment, David Guelzow has been named account director responsible for Midwest business development and support. Before joining Catalent, Mr. Guelzow worked for several years as sales manager for Amcor Flexibles Healthcare. He earned an MBA from the University of St. Thomas.

Catalent has promoted John Kay to director of operations for the printed components business of its packaging services segment. Mr. Kay was previously director of technical operations for Catalent. He holds a master's degree in industrial administration with a concentration in operations management and finance from Carnegie Mellon University.

Kevin Tilley has joined Catalent's printed compo-

nents business as account manager, with responsibility for the sales of printed components to new and existing customers in the pharmaceutical, life-sciences, and medical-device markets. Mr. Tilley most recently was an account executive for MeadWestvaco.

For more information, visit catalent.com, or stop by Booth No. 1349.

Robert Fetterman

WCC Hires Associate Director of Imaging

WorldCare Clinical (WCC), an imaging CRO for clinical trials in the pharmaceutical, biotechnology, and medical-device industries, has appointed Robert Fetterman associate director of imaging services.

Mr. Fetterman has more than two decades of experience developing and managing imaging trial processes in clinical, academic, and industry laboratories. He most recently served as associate director of imaging science at Acusphere.

For more information, visit wccclinical.com, or stop by Booth No. 1501.

John Foster

ProTrials Research Expands Executive Team

John Foster has joined specialized CRO ProTrials

Research as director of business development. In this newly created position, Mr. Foster leads ProTrials' strategic business and sales initiatives to manage the company's accelerating growth within the pharmaceutical, biotechnology, and medical device industries.

Before joining ProTrials, Mr. Foster was with Covance.

For more information, visit protrials.com, or stop by Booth No. 1215.

Douglas VanOort

NeoGenomics Taps Chairman, Interim CEO

NeoGenomics, a provider of cancer genetics testing services, has appointed Douglas VanOort executive chairman and interim CEO. Mr. VanOort's 30-year career includes more than 10 years in healthcare services, including stints as executive VP and chief financial officer of Corning Life Sciences and senior VP, operations, at Quest Diagnostics. He currently serves as operating partner for Summer Street Capital Partners and managing director of Conundrum Capital Partners.

For more information, visit neogenomics.org, or stop by Booth No. 1848.

FEATURED DIA EXHIBITING COMPANIES AT A GLANCE

AAI Pharma Inc. is a global company providing services that span the entire drug development spectrum. For more information, visit aaipharma.com or Booth No. 445.

ACM Global Central Laboratory offers a flexible approach and a focus on precision to keep clinical research studies on schedule. For more information, visit acmgloballab.com or Booth No. 726.

Acorn CRO is a full-service, oncology-focused contract research organization. For more information, visit acorncro.com or Booth No. 2039.

Ambry Genetics Corp. is a clinical laboratory providing genetic services focused on clinical diagnostics, pharmacogenomics, and research support. For more information, visit ambrygen.com or Booth No. 2047.

Catalent Pharma Solutions Inc. is a provider of development, manufacturing, and packaging services. For more information, visit catalent.com or Booth No. 1349.

Compliance Implementation Services specializes in establishing a culture of compliance for companies. For more information, visit cis-partners.com or Booth No. 2242.

Covance Inc. is a comprehensive drug-development services company. For more information, visit covance.com or Booth No. 1515.

Image Solutions Inc. is a provider of software and services to streamline the regulatory approval process in the life-sciences industry. For more information, visit imagesolutions.com or Booth No. 851.

Johnson & Johnson Pharmaceutical Research & Development LLC leverages drug discovery and development in a variety of therapeutic areas to address unmet medical needs. For more information, visit jnipharmarnd.com or Booth No. 216.

MDS Pharma Services offers a full spectrum of resources to meet drug-discovery and development needs. For more information, visit mdsps.com or Booth No. 721.

Medifacts International Inc. supports cardiovascular safety and efficacy data collection. For more information, visit medifacts.com or Booth No. 2125.

Microsoft Corp. provides software, services, and solutions. For more information, visit microsoft.com or Booth No. 931.

NeoGenomics Inc. is a CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. For more information, visit neogenomics.org or Booth 1848.

Perceptive Informatics, a subsidiary of Parexel International Corp., is a provider of e-clinical solutions. For more information, visit perceptive.com or Booth No. 1707.

Phase Forward provides integrated data collection and data management solutions for clinical trials and drug safety. For more information, visit phaseforward.com or Booth No. 729.

PPD Inc. is a global CRO providing discovery, development, and post-approval services and compound partnering programs. For more information, visit ppdi.com or Booth No. 546.

ProTrials Research Inc. is a clinical operations firm that provides qualified professionals to clinical research and development programs. For more information, visit protrials.com or Booth No. 1215.

Relsys International provides pharmacovigilance and risk management solutions to the life-sciences industry that improve product safety and ensure ongoing compliance with global regulations. For more information, visit relsys.net or Booth No. 1621.

Velos Inc. is a provider of next-generation healthcare software. For more information, visit velos.com or Booth No. 1840.

Wolters Kluwer Health is a provider of information for professionals and students in medicine, nursing, allied health, pharmacy, and the pharmaceutical industry. For more information, visit wkhealth.com or Booth No. 1842.